References: 1. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. doi:10.1186/1750-1172-5-30. 2. Street NJ, Yi MS, Bailey LA, Hopkin RJ. Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy population, and patients with other chronic disease. Genet Med. 2006;8(6):346-353. doi: 10.1097/01.gim.0000223545.63012.5a. 3. Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med. 2007;9(1):34-45. doi:10.1097/GIM.0b013e31802d8321. 4. Bouwman MG, Rombach SM, Schenk E, et al. Prevalence of symptoms in female Fabry disease patients: a case-control survey. J Inherit Metab Dis. 2012;35:891-898. doi:10.1007/s10545-011-9447-9. 5. Holmes H, Laney D. A retrospective survey studying the impact of Fabry disease on pregnancy. JIMD Rep. 2015;21:57-63. doi:10.1007/8904_2014_384. 6. Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8(9):539-548. doi:10.1097/01.gim.0000237866.70357.c6. 7. Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416-427. doi:10.1016/j.ymgme.2018.02.014.